Ontario Teachers Pension Plan Board Takes Position in Amicus Therapeutics, Inc. (FOLD)

Share on StockTwits

Ontario Teachers Pension Plan Board acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the second quarter, HoldingsChannel reports. The institutional investor acquired 52,269 shares of the biopharmaceutical company’s stock, valued at approximately $816,000.

A number of other hedge funds also recently added to or reduced their stakes in FOLD. Exane Derivatives acquired a new position in Amicus Therapeutics in the 2nd quarter valued at approximately $137,000. P.R. Herzig & Co. Inc. acquired a new position in Amicus Therapeutics in the 2nd quarter valued at approximately $156,000. Quantitative Systematic Strategies LLC acquired a new position in Amicus Therapeutics in the 2nd quarter valued at approximately $179,000. Palisade Capital Management LLC NJ acquired a new position in Amicus Therapeutics in the 1st quarter valued at approximately $211,000. Finally, TCW Group Inc. acquired a new position in Amicus Therapeutics in the 2nd quarter valued at approximately $245,000.

In other news, CFO William D. Baird III sold 10,000 shares of the stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $15.63, for a total transaction of $156,300.00. Following the completion of the sale, the chief financial officer now directly owns 117,622 shares in the company, valued at $1,838,431.86. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Kurt J. Andrews sold 5,000 shares of the stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $15.63, for a total transaction of $78,150.00. Following the sale, the senior vice president now owns 40,469 shares of the company’s stock, valued at $632,530.47. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.

FOLD opened at $12.12 on Friday. Amicus Therapeutics, Inc. has a twelve month low of $11.94 and a twelve month high of $17.62. The company has a quick ratio of 10.73, a current ratio of 10.88 and a debt-to-equity ratio of 0.30. The firm has a market cap of $2.44 billion, a PE ratio of -4.15 and a beta of 1.26.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.33). Amicus Therapeutics had a negative net margin of 460.04% and a negative return on equity of 53.45%. The company had revenue of $21.31 million during the quarter, compared to analysts’ expectations of $18.92 million. research analysts anticipate that Amicus Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Several equities analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 10th. BidaskClub cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, June 8th. ValuEngine cut shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 19th. Finally, Chardan Capital cut shares of Amicus Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the company from $18.00 to $15.00 in a research report on Friday, August 17th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $19.43.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Featured Story: Stop Order

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply